The estimated Net Worth of Cheryl R Blanchard is at least $5.13 Million dollars as of 11 March 2024. Dr Blanchard owns over 64,480 units of Anika Therapeutics stock worth over $4,031,029 and over the last 9 years he sold ANIK stock worth over $0. In addition, he makes $1,101,958 as Pres und CEO & Director at Anika Therapeutics.
Sign up
Dr D ANIK stock SEC Form 4 insiders trading
Dr has made over 10 trades of the Anika Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 64,480 units of ANIK stock worth $1,563,640 on 11 March 2024.
The largest trade he's ever made was exercising 64,480 units of Anika Therapeutics stock on 11 March 2024 worth over $1,563,640. On average, Dr trades about 7,325 units every 49 days since 2015. As of 11 March 2024 he still owns at least 166,228 units of Anika Therapeutics stock.
You can see the complete history of Dr Blanchard stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Cheryl Renee Blanchard Ph.D. biography
Dr. Cheryl Renee Blanchard Ph.D. is the Pres, CEO & Director at Anika Therapeutics.
What is the salary of Dr D?
As the Pres und CEO & Director of Anika Therapeutics, the total compensation of Dr D at Anika Therapeutics is $1,101,958. There are 2 executives at Anika Therapeutics getting paid more, with James Loerop having the highest compensation of $1,479,630.
How old is Dr D?
Dr D is 57, he's been the Pres und CEO & Director of Anika Therapeutics since . There are 8 older and 8 younger executives at Anika Therapeutics. The oldest executive at Anika Therapeutics Inc. is Joseph Bower, 81, who is the Independent Chairman of the Board.
What's Dr D's mailing address?
Cheryl's mailing address filed with the SEC is 32 WIGGINS AVENUE, , BEDFORD, MA, 01730.
Insiders trading at Anika Therapeutics
Over the last 21 years, insiders at Anika Therapeutics have traded over $58,649,775 worth of Anika Therapeutics stock and bought 34,227 units worth $758,329 . The most active insiders traders include Charles H Sherwood, Farmaceutici S.P.A. Fidia und Joseph H Capper. On average, Anika Therapeutics executives and independent directors trade stock every 47 days with the average trade being worth of $613,258. The most recent stock trade was executed by Cheryl R Blanchard on 11 March 2024, trading 64,480 units of ANIK stock currently worth $1,563,640.
What does Anika Therapeutics do?
who we are we are anika therapeutics, a global medical technology company at the forefront of pain management, tissue regeneration and wound healing. we are committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. with over 7 million procedures performed over the past twenty years utilizing our proprietary technology, anika is helping individuals all over the world return to life naturally. our guiding principles we are innovators and creators. we value strong discipline and exceptional focus from our personnel, and we employ lean principles and agile processes in managing our business. this foundation of guiding values, combined with our entrepreneurial spirit, gives anika the ability and fortitude to generate innovative ideas and to grow our portfolio of successful products. what we do anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care an
What does Anika Therapeutics's logo look like?
Complete history of Dr Blanchard stock trades at Anika Therapeutics, SeaSpine Corp, Dare Bioscience Inc und Neuronetics Inc
Anika Therapeutics executives and stock owners
Anika Therapeutics executives and other stock owners filed with the SEC include:
-
James Loerop,
Executive Vice President - Business Development and Strategic Planning -
Thomas Finnerty,
Executive Vice President of Human Resources -
Dr. Cheryl Renee Blanchard Ph.D.,
Pres, CEO & Director -
David Colleran,
Exec. VP, Gen. Counsel & Corp. Sec. -
James Loerop,
Exec. VP of Bus. Devel. & Strategic Planning -
Michael L. Levitz,
Exec. VP, CFO & Treasurer -
Thomas M. Finnerty,
Exec. VP of HR -
Joseph Bower,
Independent Chairman of the Board -
Jeffery Thompson,
Independent Director -
Raymond Land,
Independent Director -
Glenn Larsen,
Independent Director -
Cheryl Blanchard,
President, Chief Executive Officer, Director -
Susan Vogt,
Independent Director -
Dr. Cheryl R. Blanchard,
Pres, CEO & Director -
Stephen Richard,
Independent Director -
John Henneman,
Independent Director -
David Colleran,
Executive Vice President, General Counsel, Secretary -
Michael Levitz,
Chief Financial Officer, Executive Vice President, Treasurer -
Anne Nunes,
VP of Operations -
Bart Bracy,
VP of Sales & Marketing of Americas -
James Chase,
Sr. VP of International Sales & Marketing -
Charles Sherwood III,
VP & Corp. Legal Counsel -
Mark Namaroff,
Exec. Director of Investor Relations & Corp. Communications -
Alexei Goraltchouk,
Sr. VP of Operations & Project Management -
Richard Hague,
Chief Commercial Officer -
Edward S. Ahn,
Chief Tech. & Strategy Officer -
Charles H Sherwood,
President and CEO -
Sylvia Cheung,
Chief Financial Officer -
Steve E Wheeler,
Director -
Dana M. Alexander,
Chief Operations Officer -
Stephen R. Mascioli,
Chief Medical Officer -
John C Moran,
Director -
Joseph G Darling,
President and CEO; Director -
Gary P Fischetti,
Director -
Sheryl L Conley,
Director -
John W Jr Sheets,
Chief Scientific Officer -
Farmaceutici S.P.A. Fidia,
10% owner -
Peter Litman,
VP, Business Development -
William J Knight,
Chief Financial Officer -
Harvey S Sadow,
Director -
William Mrachek,
V.P., Human Resources -
Samuel F Mckay,
Director -
Eugene A Davidson,
Director -
Francesco J Luppino,
Chief Operating Officer -
Carol A Barnett,
Chief Commercial Officer -
Kevin W Quinlan,
Chief Financial Officer -
Constance H Garrison,
VP Reg.,Clinical & Qlty. Sys. -
James E O Neill,
Chief Accounting Officer -
Carol A Toth,
Vice President, R & D -
Elizabeth Chen,
Sr. VP Mktg. & Bus. Dev. -
Anne Nunes,
SVP, Chief Operations Officer -
Stephen D. Griffin,
EVP, CFO and Treasurer -
Joseph H Capper,
Director -
William R Jellison,
Director